BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pocock SJ, Clayton TC, Stone GW. Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials. J Am Coll Cardiol 2015;66:2757-66. [PMID: 26700838 DOI: 10.1016/j.jacc.2015.10.036] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Ma LL, Qiu Y, Song MN, Chen Y, Qu JX, Li BH, Zhao MJ, Liu XC. Clinical Trial Registration and Reporting: Drug Therapy and Prevention of Cardiac-Related Infections. Front Pharmacol 2019;10:757. [PMID: 31333470 DOI: 10.3389/fphar.2019.00757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Fell DB, Omer SB, Edwards KM. Influenza immunization during pregnancy: toward a balanced assessment of safety evidence. Hum Vaccin Immunother 2019;15:2165-7. [PMID: 31009301 DOI: 10.1080/21645515.2019.1599679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Gao Y, Wang Y, Li R, Zhou X. Comprehensive Analysis of Clinical Trials Registration for Lupus Nephritis Therapy on ClinicalTrials.gov. Front Med (Lausanne) 2021;8:680302. [PMID: 34222288 DOI: 10.3389/fmed.2021.680302] [Reference Citation Analysis]
4 Lorenzen US, Buggeskov KB, Nielsen EE, Sethi NJ, Carranza CL, Gluud C, Jakobsen JC. Coronary artery bypass surgery plus medical therapy versus medical therapy alone for ischaemic heart disease: a protocol for a systematic review with meta-analysis and trial sequential analysis. Syst Rev 2019;8:246. [PMID: 31661026 DOI: 10.1186/s13643-019-1155-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ji Y, Hu C, Chen Z, Li Y, Dai J, Zhang J, Shu Q. Clinical trials of stem cell-based therapies for pediatric diseases: a comprehensive analysis of trials registered on ClinicalTrials.gov and the ICTRP portal site. Stem Cell Res Ther 2022;13:307. [PMID: 35841064 DOI: 10.1186/s13287-022-02973-2] [Reference Citation Analysis]
6 Rossello X, Yellon DM. A critical review on the translational journey of cardioprotective therapies! International Journal of Cardiology 2016;220:176-84. [DOI: 10.1016/j.ijcard.2016.06.131] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
7 Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, Cushman WC, Gansevoort RT, Fellström B, Garza D, Guzman N, Holtkamp FA, London GM, Massy ZA, Mebazaa A, Mol PGM, Pfeffer MA, Rosenberg Y, Ruilope LM, Seltzer J, Shah AM, Shah S, Singh B, Stefánsson BV, Stockbridge N, Stough WG, Thygesen K, Walsh M, Wanner C, Warnock DG, Wilcox CS, Wittes J, Pitt B, Thompson A, Zannad F. Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. Eur Heart J 2019;40:880-6. [PMID: 28431138 DOI: 10.1093/eurheartj/ehx209] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
8 Gaudino M, Brophy JM. The controversy on the treatment of left main coronary artery disease. J Thorac Cardiovasc Surg 2020:S0022-5223(20)33039-7. [PMID: 33640131 DOI: 10.1016/j.jtcvs.2020.08.122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Hui SK, Sharma A, Docherty K, McMurray JJV, Pitt B, Dickstein K, Pfeffer MA, Girerd N, Rossignol P, Ferreira JP, Zannad F. Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. Eur Heart J Acute Cardiovasc Care 2021;10:127-31. [PMID: 33620418 DOI: 10.1093/ehjacc/zuaa012] [Reference Citation Analysis]
10 Angeli F, Verdecchia P, Reboldi G. Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals. Am J Cardiovasc Drugs 2020;20:229-38. [PMID: 31650521 DOI: 10.1007/s40256-019-00378-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Shillington K, Thompson C, Saraga S, Soch L, Asomaning N, Borgundvaag B, McLeod SL. The Effect of a Nurse Initiated Therapeutic Conversation Compared to Standard Care for Patients With Acute Pain in the ED: A Randomized Controlled Trial. Adv Emerg Nurs J 2021;43:217-24. [PMID: 34397500 DOI: 10.1097/TME.0000000000000363] [Reference Citation Analysis]
12 Lucena C, Souza EM, Voinea GC, Pulgar R, Valderrama MJ, De-deus G. A quality assessment of randomized controlled trial reports in endodontics. Int Endod J 2017;50:237-50. [DOI: 10.1111/iej.12626] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
13 Nielsen EE, Feinberg J, Wetterslev J, Gluud C, Jakobsen JC; Cochrane Heart Group. Non-acute percutaneous coronary intervention versus medical therapy in patients with ischaemic heart disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Pocock SJ, Rossello X, Owen R, Collier TJ, Stone GW, Rockhold FW. Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;78:827-39. [PMID: 34412817 DOI: 10.1016/j.jacc.2021.06.024] [Reference Citation Analysis]
15 Brown LK, Javaheri S, Khayat R. A Critical Review of SERVE-HF Follow-Up Studies and Their Impact on Clinical Practice. Curr Sleep Medicine Rep 2020;6:149-56. [DOI: 10.1007/s40675-020-00177-9] [Reference Citation Analysis]
16 Nielsen EE, Feinberg J, Greenhalgh J, Hounsome J, Sethi NJ, Safi S, Gluud C, Jakobsen JC; Cochrane Heart Group. Drug-eluting stents versus bare-metal stents for stable ischaemic heart disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012480] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Kurtin SE, Taher R. Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology. J Adv Pract Oncol 2020;11:736-51. [PMID: 33575069 DOI: 10.6004/jadpro.2020.11.7.7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Drexel H, Rosano GMC, Lewis BS, Huber K, Vonbank A, Dopheide JF, Mader A, Niessner A, Savarese G, Wassmann S, Agewall S. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. European Heart Journal - Cardiovascular Pharmacotherapy 2020;6:97-103. [DOI: 10.1093/ehjcvp/pvz029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
19 Feinberg J, Nielsen EE, Greenhalgh J, Hounsome J, Sethi NJ, Safi S, Gluud C, Jakobsen JC. Drug-eluting stents versus bare-metal stents for acute coronary syndrome. Cochrane Database Syst Rev 2017;8:CD012481. [PMID: 28832903 DOI: 10.1002/14651858.CD012481.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
20 Fuster V. Editor-in-Chief's Top Picks From 2015: Part Two. J Am Coll Cardiol 2016;67:817-42. [PMID: 26892419 DOI: 10.1016/j.jacc.2015.12.003] [Reference Citation Analysis]
21 Funck-brentano C. Indispensable but deceptive evidence-based medicine. Diabetes & Metabolism 2020;46:415-22. [DOI: 10.1016/j.diabet.2020.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ndrepepa G, Neumann FJ, Menichelli M, Bernlochner I, Richardt G, Wöhrle J, Witzenbichler B, Mayer K, Cassese S, Gewalt S, Xhepa E, Kufner S, Sager HB, Joner M, Ibrahim T, Laugwitz KL, Schunkert H, Schüpke S, Kastrati A. Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes. J Am Heart Assoc 2021;10:e021418. [PMID: 34779234 DOI: 10.1161/JAHA.121.021418] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Barbateskovic M, Schjørring OL, Jakobsen JC, Meyhoff CS, Rasmussen BS, Perner A, Wetterslev J. Oxygen supplementation for critically ill patients-A protocol for a systematic review. Acta Anaesthesiol Scand 2018;62:1020-30. [PMID: 29708586 DOI: 10.1111/aas.13127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Fuster V. Unraveling the Complexities of Statistical Presentation. Journal of the American College of Cardiology 2015;66:2909-10. [DOI: 10.1016/j.jacc.2015.11.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
25 Aghel N, Delgado DH, Lipton JH. Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines? Leukemia 2018;32:2095-104. [PMID: 30201984 DOI: 10.1038/s41375-018-0247-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Cheng Q, Chen J, Jia Q, Fang Z, Zhao G. Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials. Aging (Albany NY) 2021;13:21866-902. [PMID: 34531332 DOI: 10.18632/aging.203522] [Reference Citation Analysis]
27 Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2018;41:14-31. [PMID: 29263194 DOI: 10.2337/dci17-0057] [Cited by in Crossref: 258] [Cited by in F6Publishing: 211] [Article Influence: 64.5] [Reference Citation Analysis]
28 Barbateskovic M, Schjørring OLL, Jakobsen JC, Meyhoff CS, Dahl RM, Rasmussen BS, Perner A, Wetterslev J; Cochrane Emergency and Critical Care Group. Higher versus lower inspiratory oxygen fraction or targets of arterial oxygenation for adult intensive care patients. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012631] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
29 Barbateskovic M, Schjørring OL, Russo Krauss S, Jakobsen JC, Meyhoff CS, Dahl RM, Rasmussen BS, Perner A, Wetterslev J. Higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit. Cochrane Database Syst Rev 2019;2019. [PMID: 31773728 DOI: 10.1002/14651858.CD012631.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
30 Angeli F, Verdecchia P, Vaudo G, Masnaghetti S, Reboldi G. Optimal Use of the Non-Inferiority Trial Design. Pharmaceut Med 2020;34:159-65. [PMID: 32277352 DOI: 10.1007/s40290-020-00334-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
31 Guimarães PO, Lopes RD, Stevens SR, Zimerman A, Wruck L, James SK, Haque G, Giraldez RRCV, Alexander JH, Alexander KP. Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. J Am Heart Assoc 2017;6:e005490. [PMID: 28438739 DOI: 10.1161/JAHA.117.005490] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
32 Cowie MR, Filippatos GS, Alonso Garcia MLA, Anker SD, Baczynska A, Bloomfield DM, Borentain M, Bruins Slot K, Cronin M, Doevendans PA, El-Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen H, Kim AM, Lautsch D, Laws I, Lefkowitz M, Lopez-Sendon J, Lyon AR, Malik FI, McMurray JJV, Metra M, Figueroa Perez S, Pfeffer MA, Pocock SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano GMC, Sherman W, Stough WG, Swedberg K, Tyl B, Zannad F, Boulton C, De Graeff P. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. Eur J Heart Fail 2017;19:718-27. [PMID: 28345190 DOI: 10.1002/ejhf.809] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
33 Ingram MA, Jones MB, Stonehouse W, Jarrett P, Scragg R, Mugridge O, von Hurst PR. Oral vitamin D3 supplementation for chronic plaque psoriasis: a randomized, double-blind, placebo-controlled trial. J Dermatolog Treat 2018;29:648-57. [PMID: 29480035 DOI: 10.1080/09546634.2018.1444728] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
34 Romero A, Llauradó G, González-Clemente JM. Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type2 diabetes. Endocrinol Diabetes Nutr (Engl Ed) 2021:S2530-0164(21)00084-7. [PMID: 33965366 DOI: 10.1016/j.endinu.2020.12.004] [Reference Citation Analysis]
35 Zheutlin AR, Caldwell DJ, Al Danaf J, Shah RU. Prevalence of control groups in cardiovascular clinical trials: An analysis of ClinicalTrials.gov from 2009 through 2019. Am Heart J 2021;234:133-5. [PMID: 33347871 DOI: 10.1016/j.ahj.2020.12.006] [Reference Citation Analysis]
36 Nguyen TL, Collins GS, Lamy A, Devereaux PJ, Daurès JP, Landais P, Le Manach Y. Simple randomization did not protect against bias in smaller trials. J Clin Epidemiol 2017;84:105-13. [PMID: 28257927 DOI: 10.1016/j.jclinepi.2017.02.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
37 Schoenfeld DA, Ramchandani R, Finkelstein DM. Designing a longitudinal clinical trial based on a composite endpoint: Sample size, monitoring, and adaptation. Stat Med 2022. [PMID: 35818331 DOI: 10.1002/sim.9416] [Reference Citation Analysis]